Table A1.
Multivariable HRs for AC Use and Prostate Cancer–Specific Mortality Using Fine and Gray's Competing Risks Model
| Covariate | Parameter | HR | 95% CI | P |
|---|---|---|---|---|
| Aspirin* | Yes v no (referent) | 0.14 | 0.05 to 0.44 | < .01 |
| AC, no aspirin* | Yes v no (referent) | 0.40 | 0.12 to 1.35 | .14 |
| Initial PSA (log) | Per ng/mL | 1.72 | 1.38 to 2.14 | < .01 |
| Gleason score | 2-6 (referent) | 1.00 | — | |
| 7 | 1.31 | 0.81 to 2.11 | .28 | |
| 8-10 | 4.78 | 2.96 to 7.73 | < .01 | |
| Clinical T stage | T1-T2a (referent) | 1.00 | — | |
| T2b-c | 2.52 | 1.69 to 3.76 | < .01 | |
| T3a-T4 | 3.64 | 1.70 to 7.79 | < .01 | |
| Treatment modality | RP (referent) | 1.00 | — | |
| RT alone | 2.11 | 1.40 to 3.18 | < .01 | |
| RT + ADT | 1.12 | 0.62 to 2.00 | .71 |
Abbreviations: AC, anticoagulant; ADT, androgen deprivation therapy; HR, hazard ratio; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiotherapy.
*
Updated as time-dependent variables.